CEACAM1 and melanoma: Based on these findings, we have raised an anti-CEACAM1 blocking antibody that renders melanoma cells more vulnerable to cytotoxic immune cells both in vitro and in vivo and is a promising strategy for treating melanoma patients [4, 10].